CLINICAL_TRIALS
withdrawal
· 2014-01-06
Clinical Trial Update: IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) [Phase 2]
Summary
Clinical trial update notes that the Phase 2 study of idelalisib (IPI-145) in relapsed/refractory acute lymphoblastic leukemia has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: WITHDRAWN